510(k) vs De Novo: which pathway fits your device

Use a 510(k) when a legally marketed predicate shares your intended use and your technological differences do not raise different questions of safety and effectiveness. Use De Novo when no such predicate exists and your device is low to moderate risk; high-risk devices with no predicate go to PMA.
Written by the Bearnier AI team · Updated Oct 12, 2026 · 6 min read
1

Look for a predicate with the same intended use

A 510(k) argues substantial equivalence to a legally marketed device. Start with your product code and read the intended use in recent summaries; if none match yours, a 510(k) is unlikely to work.

2

Compare technological characteristics

Differences in technology are allowed when they do not raise different questions of safety and effectiveness and your testing answers them. A new energy source, a new kind of output or a new patient population often does raise new questions.

3

If there is no predicate, judge the risk

De Novo is for novel devices of low to moderate risk that general controls, or general and special controls, can make reasonably safe. Novel high-risk devices need a PMA instead.

4

Confirm the pathway in a Pre-Sub

When the answer is not clear, a Pre-Submission meeting lets you ask FDA about the pathway, the predicate and the testing before you commit to either.

5

Plan for different evidence and timelines

FDA’s review goal is 90 FDA days for a 510(k) and 150 review days for a De Novo, and De Novo user fees are several times higher. A De Novo also needs a proposed classification, special controls and a fuller benefit-risk case.

6

Remember what a De Novo creates

A granted De Novo creates a new classification regulation and product code, and the device becomes a predicate. Later devices of the same type, including your own next version, can then use the 510(k) pathway against it.

Try it on your device

Describe the device; Bearnier AI lists candidate predicates and the De Novo decisions behind its device type.

US FDA devices: 510(k), De Novo, guidance, 21 CFR
Get new guides in The Clearance LogOne email every Monday. Five minutes, every item cited.

Questions

Can I file a De Novo after a 510(k) is found not substantially equivalent?

Yes. A De Novo request can follow a not-substantially-equivalent decision, or you can submit one directly when you believe no predicate exists.

Does a De Novo device become a predicate?

Yes. Once granted, the device is legally marketed and can serve as a predicate for later 510(k)s of the same type.

Which is faster?

Usually the 510(k): FDA’s review goal is 90 FDA days, against 150 review days for a De Novo, and a 510(k) needs less new evidence.

Know what FDA already cleared.